NKX3-1
Overview
NKX3-1 is a homeobox transcription factor. In the corpus it appears as a gene whose alterations associate with local intracranial progression of NSCLC brain metastases.
Alterations observed in the corpus
- Alterations enriched in local intracranial progressors after craniotomy + RT for LUAD brain metastases (16% vs 3% in non-progressors; p=0.044) PMID:37591896.
- Recurrent post-treatment alteration and association with Gleason/metastasis in PRAD in the MSK-CHORD pan-cancer real-world cohort (n=52,211); NKX3-1 listed alongside AR, CDK12, and FOXA1 as recurrent post-treatment PRAD alterations. PMID:39506116
- Recurrently deleted in prostate cancer identified in integrative genomic profiling of 218 tumors PMID:20579941
- NKX3-1 somatic mutations detected in prostate cancer; identified in WES of 112 primary tumors (Broad Institute cohort) PMID:22610119
- Strictly clonal deletion in 8 of 26 prostate tumors via chromoplexy; identified as one of the earliest detectable lesions in prostate carcinogenesis based on clonality analysis (p=10⁻⁵ for NKX3-1 deletion being earlier than PTEN) PMID:23622249
- Significantly mutated in prostate adenocarcinoma (somatic mutation in ~1%); also commonly deleted; listed among significantly mutated genes in the TCGA cohort (n=333) PMID:26544944
Cancer types (linked)
- Lung adenocarcinoma (LUAD) — associated with local intracranial progression PMID:37591896.
Co-occurrence and mutual exclusivity
- Local-progression group also enriched for RB1 loss PMID:37591896.
Therapeutic relevance
- No direct therapeutic link reported in the corpus.
Open questions
- Mechanism linking NKX3-1 alteration to local CNS recurrence is untested.
Sources
This page was processed by crosslinker on 2026-05-09. - PMID:20579941
This page was processed by crosslinker on 2026-05-09. - PMID:22610119
This page was processed by crosslinker on 2026-05-09. - PMID:23622249
This page was processed by crosslinker on 2026-05-09. - PMID:26544944
This page was processed by wiki-cli on 2026-05-14.